Ping Capital Management Inc. Acquires 1,000 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

Ping Capital Management Inc. increased its holdings in ARK Genomic Revolution ETF (BATS:ARKG) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,000 shares of the company’s stock after buying an additional 1,000 shares during the period. Ping Capital Management Inc.’s holdings in ARK Genomic Revolution ETF were worth $353,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in ARK Genomic Revolution ETF by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock worth $75,655,000 after purchasing an additional 698,701 shares in the last quarter. Barclays PLC increased its holdings in shares of ARK Genomic Revolution ETF by 252.7% in the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after buying an additional 204,283 shares during the last quarter. PFM Health Sciences LP purchased a new stake in ARK Genomic Revolution ETF during the third quarter valued at about $2,226,000. Quadrature Capital Ltd purchased a new position in shares of ARK Genomic Revolution ETF in the 3rd quarter worth about $1,970,000. Finally, Elmwood Wealth Management Inc. raised its holdings in shares of ARK Genomic Revolution ETF by 7.7% during the 4th quarter. Elmwood Wealth Management Inc. now owns 62,191 shares of the company’s stock valued at $1,464,000 after buying an additional 4,425 shares in the last quarter.

ARK Genomic Revolution ETF Trading Up 13.7 %

Shares of BATS:ARKG opened at $26.85 on Wednesday. The company’s 50-day moving average is $25.31 and its 200-day moving average is $25.20.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.